Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of GLY-LOW Supplementation in Postmenopausal Obesity
NCT06242535Phase 1Completed
- Sponsor
- Hoskinson Health and Wellness Clinic
- Start
- Jul 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Gly-low in obesity and insulin resistance (IR), sponsored by Hoskinson Health and Wellness Clinic. Primary endpoints: Insulin Resistance at 6 months, Fasting Insulin at 6 months and 4 more. Started Jul 2023; status: completed.
02
Drugs
Gly-low
03
Conditions
obesityinsulin resistance (IR)
Beyond the preview
Go deeper on NCT06242535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06242535.